Efficacy and Safety of Oral Bosentan on Healing/Prevention of Digital (Finger) Ulcers in Patients With Scleroderma
Status:
Completed
Trial end date:
2005-05-01
Target enrollment:
Participant gender:
Summary
In an earlier clinical trial, RAPIDS-1, conducted in scleroderma patients with or without
digital ulcers at baseline, bosentan significantly reduced the number of new digital ulcers
versus placebo. The purpose of the present trial (RAPIDS-2) is to evaluate the prevention and
healing effects of bosentan versus placebo on digital ulcers over a 24-week treatment period.